Glucagon-like peptide-1 vs Survodutide
The incretin that anchors the modern metabolic toolkit. A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Glucagon-like peptide-1 GLP-1 | Survodutide BI 456906 | |
|---|---|---|
| Also known as | — | — |
| Type | Endogenous | Analog |
| Evidence | Established | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Proglucagon-derived peptide (~30–31 aa) | Glucagon/GLP-1 dual receptor agonist (acylated peptide) |
| Receptor / target | GLP-1 receptor (GLP-1R), a class B GPCR | Glucagon receptor (GCGR) + GLP-1 receptor |
| Molecular weight | ~3,297.7 Da | ≈4,800 Da |
| Half-life | engineered for once-weekly dosing | |
| Based on | Native hormone | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Glucagon-like peptide-1 and Survodutide?
- Glucagon-like peptide-1 is an endogenous hormone; Survodutide is an engineered analog based on Glucagon-like peptide-1. Glucagon-like peptide-1 signals at GLP-1 receptor (GLP-1R), a class B GPCR; Survodutide signals at Glucagon receptor (GCGR) + GLP-1 receptor.
- How do the half-lives of GLP-1 and BI 456906 compare?
- The reported circulating half-life of Glucagon-like peptide-1 is ~1–2 min (native; DPP-4 cleaved); Survodutide is engineered for once-weekly dosing. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Survodutide vs Glucagon-like peptide-1. Or open the interactive comparison tool to add more molecules.